Exenatide tracker
Educational reference for Exenatide. Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
2.4 h
Tmax
2 h
Category
glp1
Also known as: Byetta, Bydureon, exendin-4
> PLACEHOLDER — pending clinical review by licensed pharmacist. Exenatide is an FDA-approved GLP-1 receptor agonist for type 2 diabetes. Subcutaneous injection.
Mechanism
A GLP-1 receptor agonist derived from exendin-4, a peptide originally identified in Gila monster venom. It resists rapid degradation relative to native GLP-1 and is associated with glucose-dependent insulin secretion, slowed gastric emptying, and reduced appetite.
Research summary
One of the earliest approved GLP-1 receptor agonists for type 2 diabetes, available in twice-daily and extended-release once-weekly formulations. Marketed as Byetta and Bydureon.
Dosing in the literature
Trials evaluated subcutaneous administration in immediate-release and extended-release forms. Specific regimens are individualized and set by a prescribing clinician; they are outside the scope of this summary.
Reported side effects
Gastrointestinal effects (nausea, vomiting, diarrhea) are most commonly reported. Prescribing information includes warnings such as pancreatitis and, for the extended-release form, thyroid C-cell tumor risk in rodents. This is not a complete safety profile.
Stacking notes
Combination with insulin or sulfonylureas raises hypoglycemia considerations and is a clinical decision.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- Exenatide clinical development in type 2 diabetes · peer-reviewed clinical trials (2005)search PubMed for exenatide type 2 diabetes
- Byetta / Bydureon prescribing information · FDA prescribing information (2012)available via DailyMed / accessdata.fda.gov
Track Exenatide in TrackPep
Reconstitution calculator, interactive body-map rotation, side-effect timeline, weight trends, and a private log — all in one place. Free to try.